Literature DB >> 20715980

Increased poly(ADP-ribose) polymerase (PARP)-1 expression and activity are associated with inflammation but not goblet cell metaplasia in murine models of allergen-induced airway inflammation.

Thomas Havranek1, Pawandeep K Aujla, Tracey J Nickola, Mary C Rose, Louis M Scavo.   

Abstract

Inflammation plays a key role in lung injury and in the pathogenesis of asthma. Two murine models of allergic airway inflammation-sensitization and challenge to ovalbumin (OVA) and intratracheal exposure to interleukin-13 (IL13)-were used to evaluate the expression of poly(ADP-ribose) polymerase-1 (PARP-1) in allergic airway inflammation. Inflammation is prominent in OVA-induced allergic asthma, but this inflammation is greatly reduced by a PARP-1 inhibitor and almost eliminated when PARP-1 knockout mice are subjected to the OVA model. The present study temporally evaluated PARP-1 protein expression, localization, and activity, as well as inflammation and goblet cell metaplasia (GCM), in murine lungs following a single OVA challenge or IL13 exposure. Following OVA challenge PARP-1 protein expression and activity were greatly increased, being maximal at 3 to 5 days following OVA exposure and beginning to decrease by day 8. These changes correlated with the timing and degree of inflammation and GCM. In contrast, PARP-1 protein or activity did not change following single IL13 exposure, though GCM was manifested without inflammation. This study demonstrates that both PARP-1 protein and activity are increased by allergen-activated inflammatory mediators, excluding IL13, and that PARP-1 increase does not appear necessary for GCM, one of the characteristic markers of allergic airway inflammation in murine models.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20715980     DOI: 10.3109/01902141003663360

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  9 in total

Review 1.  Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases.

Authors:  Xueqing Ba; Nisha Jain Garg
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

2.  PARP-1: a new player in the asthma field?

Authors:  É Szabó; I Kovács; T Grune; A Haczku; L Virág
Journal:  Allergy       Date:  2011-02-02       Impact factor: 13.146

Review 3.  Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease.

Authors:  Archana Shankar; Jaclyn W McAlees; Ian P Lewkowich
Journal:  J Allergy Clin Immunol       Date:  2022-08       Impact factor: 14.290

Review 4.  Beyond DNA repair, the immunological role of PARP-1 and its siblings.

Authors:  Maria Manuela Rosado; Elisabetta Bennici; Flavia Novelli; Claudio Pioli
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

Review 5.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

6.  Effects of PARP-1 deficiency on Th1 and Th2 cell differentiation.

Authors:  M Sambucci; F Laudisi; F Novelli; E Bennici; M M Rosado; C Pioli
Journal:  ScientificWorldJournal       Date:  2013-11-05

Review 7.  Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases.

Authors:  Simonetta Pazzaglia; Claudio Pioli
Journal:  Cells       Date:  2019-12-22       Impact factor: 6.600

Review 8.  Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach.

Authors:  Raffaela Zaffini; Giovanni Gotte; Marta Menegazzi
Journal:  Drug Des Devel Ther       Date:  2018-02-12       Impact factor: 4.162

Review 9.  Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review.

Authors:  Gurupreet S Sethi; Vivek Dharwal; Amarjit S Naura
Journal:  Front Immunol       Date:  2017-09-19       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.